PMID- 10751750
OWN - NLM
STAT- MEDLINE
DCOM- 20000531
LR  - 20221207
IS  - 1520-7552 (Print)
IS  - 2005-6648 (Electronic)
IS  - 1520-7552 (Linking)
VI  - 16
IP  - 2
DP  - 2000 Mar-Apr
TI  - Advanced glycosylation end products (AGEs), insulin-like growth factor-1 (IGF-1) 
      and IGF-binding protein-3 (IGFBP-3) in patients with type 2 diabetes mellitus.
PG  - 106-13
AB  - BACKGROUND: Advanced glycosylation end product (AGE) formation is a major 
      mechanism for the development of complications in diabetes, and the possible 
      roles of insulin-like growth factor 1 (IGF-1) and IGF binding protein 3 (IGFBP-3) 
      are not clearly established. METHODS: We examined the associations of AGEs, free 
      IGF-I and IGFBP-3 in Type 2 diabetes mellitus (DM) patients under diverse 
      conditions. In a cross-sectional design we studied 110 subjects (67 women and 43 
      men): non-diabetic controls in group 1, (n = 15) and diabetes patients as 
      follows: group 2, without complications (n = 25); group 3, with chronic 
      complications (n = 25); group 4, with acute or chronic infections (n = 24); group 
      5, hospitalized for reasons unrelated to diabetes (n = 9); group 6, with 
      end-stage renal disease (ESRD) (n = 12). AGEs were determined by a 
      spectrofluorometric method (HPLC). Insulin and IGFBP-3 were measured by RIA and 
      free IGF-1 with an IRMA method. RESULTS: AGEs were 13-fold higher in patients 
      with ESRD (p<0.001), and lower in healthy individuals. Free IGF-1 was lower in 
      the patients with complications (p = 0.017), with infections (p = 0.006) and 
      hospitalized (p = 0.04). IGFBP-3 was higher in hospitalized patients (p=0.017). 
      AGEs were associated with free IGF-1 (r = 0.41, p = 0.04) in the group with 
      complications, and with HbA(1c) (r = -0.90, p = 0.002) in hospitalized patients. 
      In the total group, free IGF-1 (r = -0.25, p = 0.008), and IGFBP-3 (r = -0.22, p 
      = 0.021) were associated with HbA(1c). CONCLUSION: We concluded that AGEs were 
      markedly increased in diabetic patients with ESRD, IGF-1 was decreased in 
      patients with infections and hospitalized, and was negatively associated with 
      HbA(1c). IGFBP-3 was increased in hospitalized patients, with higher levels in 
      patients with long bone fractures. A complex interaction of humoral factors may 
      participate in the acceleration of complications of diabetes.
FAU - Garay-Sevilla, M E
AU  - Garay-Sevilla ME
AD  - Instituto de Investigaciones Medicas, Universidad de Guanajuato, 20 de Enero 929, 
      37320 Leon Gto, Mexico.
FAU - Nava, L E
AU  - Nava LE
FAU - Malacara, J M
AU  - Malacara JM
FAU - Wrobel, K
AU  - Wrobel K
FAU - Wrobel, K
AU  - Wrobel K
FAU - Perez, U
AU  - Perez U
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 3)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - Biomarkers/blood
MH  - Blood Glucose/metabolism
MH  - Blood Pressure
MH  - Cholesterol/blood
MH  - Communicable Diseases/blood
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*blood/*complications
MH  - Diabetic Nephropathies/blood
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Glycation End Products, Advanced/*blood
MH  - Humans
MH  - Inpatients
MH  - Insulin-Like Growth Factor Binding Protein 3/*blood
MH  - Insulin-Like Growth Factor I/analysis/*metabolism
MH  - Kidney Failure, Chronic/blood
MH  - Male
MH  - Middle Aged
MH  - Reference Values
MH  - Regression Analysis
PMC - PMC2687688
EDAT- 2000/04/07 09:00
MHDA- 2000/06/03 09:00
PMCR- 2007/09/01
CRDT- 2000/04/07 09:00
PHST- 2000/04/07 09:00 [pubmed]
PHST- 2000/06/03 09:00 [medline]
PHST- 2000/04/07 09:00 [entrez]
PHST- 2007/09/01 00:00 [pmc-release]
AID - 10.1002/(SICI)1520-7560(200003/04)16:2<106::AID-DMRR88>3.0.CO;2-H [pii]
AID - 10.1002/(sici)1520-7560(200003/04)16:2<106::aid-dmrr88>3.0.co;2-h [doi]
PST - ppublish
SO  - Diabetes Metab Res Rev. 2000 Mar-Apr;16(2):106-13. doi: 
      10.1002/(sici)1520-7560(200003/04)16:2<106::aid-dmrr88>3.0.co;2-h.